Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXYCODONE AND ASPIRIN vs HYDROCODONE
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Oxycodone: mu-opioid receptor agonist; Aspirin: irreversible cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
Hydrocodone is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system, inhibiting ascending pain pathways and altering perception of pain.
Moderate to moderately severe pain,Pain with inflammation (off-label)
Management of moderate to severe pain where opioid treatment is appropriate,Off-label: Relief of cough (in combination products)
1 tablet (oxycodone 4.5 mg/aspirin 325 mg) orally every 6 hours as needed for pain; maximum 4 tablets in 24 hours.
5-10 mg orally every 4-6 hours as needed for pain; maximum 60 mg/day
Oxycodone: 3-5 hours (immediate-release); 4.5-8 hours (extended-release). Aspirin (salicylate): 2-3 hours (low dose), 15-30 hours (high dose due to saturation of metabolic pathways).
Terminal elimination half-life is approximately 3.8-4.5 hours in adults; may be prolonged in hepatic or renal impairment.
Oxycodone: hepatic via CYP3A4 and CYP2D6 to active metabolites; Aspirin: hepatic hydrolysis to salicylate, further conjugated with glycine (salicyluric acid) or glucuronic acid.
GFR 30-50 m L/min: use with caution, reduce dose or interval. GFR <30 m L/min: avoid use (accumulation of aspirin metabolites and oxycodone).
e GFR 30-89 m L/min: no adjustment; e GFR <30 m L/min: reduce dose by 50% and extend interval to every 6-8 hours; avoid in ESRD
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children); neonatal opioid withdrawal syndrome; CYP3A4 interaction with other drugs; risk of gastric mucosal injury and bleeding with aspirin.
First trimester: Aspirin is associated with increased risk of neural tube defects and cardiac malformations at high doses. Oxycodone use may be associated with neural tube defects but data are limited. Second trimester: Aspirin may impair fetal renal function and lead to oligohydramnios. Oxycodone crosses placenta; chronic use may cause fetal dependence. Third trimester: Aspirin near term increases risk of intracranial hemorrhage in neonate and premature closure of ductus arteriosus. Oxycodone may cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
First trimester: Limited human data; animal studies show no consistent teratogenicity at therapeutic doses. Opioid use in first trimester may be associated with small increased risk of neural tube defects, but absolute risk is low. Second trimester: No specific malformations reported. Third trimester: Chronic use can cause neonatal opioid withdrawal syndrome (NOWS) in up to 60% of neonates. High doses near term may increase risk of respiratory depression at birth.
Oxycodone/aspirin combines an opioid agonist with an NSAID; monitor for GI bleeding, renal impairment, and opioid-related respiratory depression. Use with caution in patients with asthma or peptic ulcer disease. Aspirin component irreversibly inhibits platelet aggregation; avoid use when a pure opioid is sufficient to minimize aspirin-related risks. Onset of analgesia occurs within 15-30 minutes; duration 4-6 hours.
Hydrocodone is a prodrug metabolized by CYP2D6 to hydromorphone, a potent mu-opioid agonist. Its analgesic effect is dependent on this conversion; therefore, CYP2D6 poor metabolizers (approx. 7-10% of population) may experience reduced analgesia. Caution in renal impairment (Cr Cl <30 m L/min) due to accumulation of parent drug and metabolites, leading to prolonged respiratory depression. Avoid concurrent use with alcohol, benzodiazepines, or other CNS depressants due to additive respiratory depression. Monitor for serotonin syndrome when used with serotonergic drugs. Use the lowest effective dose for the shortest duration; assess for opioid-induced constipation and consider prophylactic bowel regimen.
No interactions on record
"Hydrocodone, a mu-opioid receptor agonist, enhances central nervous system (CNS) depression when coadministered with ramelteon, a melatonin receptor agonist that also induces mild CNS depression. This additive pharmacodynamic effect results from convergence on common GABAergic and sedative pathways, leading to increased risks of excessive sedation, respiratory depression, cognitive impairment, and psychomotor slowing. Clinically, patients may experience extreme drowsiness, confusion, dizziness, and an elevated risk of falls or accidents, particularly during initiation or dose escalation."
"The combination of hydrocodone and rucaparib can significantly increase rucaparib serum concentrations due to competitive inhibition of CYP3A4 and CYP2D6, the primary enzymes responsible for rucaparib metabolism. This elevation in rucaparib exposure may potentiate its adverse effects, such as myelosuppression (anemia, thrombocytopenia, neutropenia) and hepatotoxicity, requiring dose adjustment or increased monitoring. The interaction is considered moderate to high risk, particularly in patients with pre-existing hepatic impairment or concurrent use of other CYP3A4/2D6 inhibitors."
"Hydrocodone, an opioid agonist, and hexobarbital, a barbiturate, both depress the central nervous system (CNS) via distinct mechanisms. Their concurrent use leads to additive or synergistic CNS depression, resulting in enhanced sedation, respiratory depression, and potentially fatal respiratory arrest. Clinical outcomes include excessive sedation, impaired psychomotor function, hypotension, and coma, particularly with high doses or in elderly patients."
OXYCODONE AND ASPIRIN and HYDROCODONE are distinct pharmacological agents. OXYCODONE AND ASPIRIN belongs to the Opioid Agonist class and is primarily used for Moderate to moderately severe painPain with inflammation (off-label). HYDROCODONE belongs to the Opioid Agonist class and is primarily used for Management of moderate to severe pain where opioid treatment is appropriateOff-label: Relief of cough (in combination products). Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. OXYCODONE AND ASPIRIN carries a safety status of Category D/X, whereas HYDROCODONE safety is classified as Category D/X. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Hepatic metabolism primarily via CYP2D6 and CYP3A4 to hydromorphone (active) and norhydrocodone (inactive).
Oxycodone: renal (primarily as noroxycodone) 87%, fecal <10%. Aspirin (as salicylate): renal 50-80% (dose-dependent; alkaline urine increases excretion), with biliary elimination of metabolites.
Renal (67%) as conjugated morphine and normorphine, norhydrocodone, and hydromorphone; fecal (negligible).
Oxycodone: 45% bound to plasma proteins (primarily albumin). Aspirin (acetylsalicylic acid): 80-90% bound to albumin; salicylic acid: 50-80% bound.
About 19-45% (primarily albumin).
Oxycodone: 2.6-3.0 L/kg (indicating extensive tissue distribution). Aspirin (salicylate): 0.15-0.20 L/kg (low Vd, primarily restricted to extracellular fluid).
Approximately 3.3-4.7 L/kg; indicates extensive tissue distribution.
Oxycodone: oral 60-87% (first-pass metabolism); rectal suppository ~50%. Aspirin: oral 40-50% (due to first-pass hydrolysis); rectal ~20-60%.
Oral immediate-release: 70-80%; oral extended-release: 70-80%; intranasal: approximately 50% (relative to oral); rectal: similar to oral.
Child-Pugh A: no adjustment recommended. Child-Pugh B: reduce oxycodone dose by 50% (e.g., start with 2.25 mg) and avoid aspirin if severe hepatic impairment. Child-Pugh C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and extend interval to every 6-8 hours; Child-Pugh C: avoid use
Not recommended for children <18 years due to risk of Reye syndrome from aspirin and lack of safety data for oxycodone.
Children ≥2 years: 0.1-0.2 mg/kg/dose orally every 4-6 hours as needed; maximum 10 mg/dose, 60 mg/day
Initiate at lowest dose (e.g., 1 tablet every 6 hours), monitor renal function and cognitive effects; avoid in patients with GFR <30 m L/min.
Start at lowest effective dose (2.5-5 mg every 4-6 hours); consider alternate opioid if renal impairment; monitor for confusion and constipation
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; and risk of overdose with ethanol.
Respiratory depression, CNS depression, opioid-induced hyperalgesia, adrenal insufficiency, hypotension, seizures, gastrointestinal bleeding (aspirin), Reye's syndrome (aspirin in children), bleeding risk, renal impairment.
Respiratory depression, decreased bowel motility, increased intracranial pressure, severe hypotension, adrenal insufficiency, opioid-induced hyperalgesia, and risk of serotonin syndrome with serotonergic drugs.
Hypersensitivity to oxycodone or aspirin, significant respiratory depression, acute or severe bronchial asthma, suspected paralytic ileus, GI obstruction, bleeding disorders, children with viral illness (Reye's syndrome), third trimester pregnancy, concomitant use with MAOIs or within 14 days.
Significant respiratory depression, acute or severe bronchial asthma, known or suspected gastrointestinal obstruction (e.g., paralytic ileus), and hypersensitivity to hydrocodone.
Avoid alcohol; increases risk of GI bleeding and hepatotoxicity. Avoid high-fat meals? Not significant. Grapefruit juice may potentiate oxycodone? Not established for oxycodone, but caution with grapefruit products is prudent. Maintain adequate hydration to prevent aspirin-related renal effects.
Avoid grapefruit and grapefruit juice during therapy as they inhibit CYP3A4 metabolism, increasing hydrocodone exposure and risk of adverse effects. High-fat meals may increase absorption of hydrocodone; advise taking with consistent meals to maintain stable levels. Alcohol is contraindicated due to additive CNS depression and increased hepatotoxicity risk. No other significant food interactions.
Oxycodone: Excreted into breast milk; relative infant dose (RID) 3-8% of maternal weight-adjusted dose. Monitor infant for drowsiness and poor feeding. Aspirin: Excreted into breast milk; high doses may cause Reye's syndrome risk in infant; generally avoid breastfeeding with high-dose aspirin. M/P ratio for oxycodone: ~3.2:1 (milk:plasma).
Hydrocodone is excreted into breast milk (M/P ratio approximately 2.0-2.5). Relative infant dose is estimated at 2-3% of maternal weight-adjusted dose. Breastfeeding is generally considered acceptable with caution; monitor infant for sedation, poor feeding, and respiratory depression. Avoid in mothers with ultra-rapid CYP2D6 metabolizers due to increased risk of morphine accumulation.
Increased plasma volume and renal clearance in pregnancy may reduce oxycodone levels; dose may need increase but cautious due to risk of dependence. Aspirin: Avoid high doses (>150 mg/day) in third trimester; low-dose aspirin for specific indications (e.g., preeclampsia prophylaxis) is standard. No routine dose adjustment for aspirin in pregnancy unless renal function changes.
Increased clearance and volume of distribution in pregnancy may require dose increases to maintain analgesia. Dose should be titrated to effective pain relief, with close monitoring for respiratory depression. If used chronically, taper gradually near term to reduce NOWS risk. No standard dose adjustment formula; individualize based on response and tolerance.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not crush or chew tablets; swallow whole.,Avoid alcohol while taking this medication; it increases risk of stomach bleeding and liver damage.,Do not drive or operate heavy machinery until you know how this drug affects you; it may cause drowsiness or dizziness.,Report any stomach pain, black/tarry stools, or vomiting blood immediately.,Stop taking and seek medical attention if you have signs of allergic reaction (rash, difficulty breathing, swelling of face/throat).,Keep out of reach of children; accidental ingestion can be fatal.,Do not take with other NSAIDs (ibuprofen, naproxen) or aspirin-containing products.
Take exactly as prescribed; do not increase dose or frequency without doctor's approval.,Do not crush, break, or chew extended-release tablets; swallow whole.,Avoid alcohol and any medications that make you drowsy (e.g., benzodiazepines, muscle relaxants) unless approved by your doctor.,This medication may cause constipation; increase fluid and fiber intake, and ask about stool softeners or laxatives.,Do not drive or operate heavy machinery until you know how this medication affects you.,Seek emergency help if you experience trouble breathing, severe drowsiness, or unresponsiveness.,Store securely out of reach of others, especially children; properly dispose of unused medication via take-back program.,Do not stop abruptly without doctor guidance to avoid withdrawal symptoms.,Report any signs of allergic reaction (rash, itching, swelling) or serotonin syndrome (agitation, hallucinations, rapid heart rate, fever, muscle stiffness) immediately.